Inositols in the Treatment of Insulin-Mediated Diseases

Giovanna Muscogiuri, Stefano Palomba, Antonio Simone Laganà, Francesco Orio

Research output: Contribution to journalReview article

Abstract

A growing body of research is currently focused on the role of inositol isomers and in particular myo-inositol (MYO-INS) and D-chiroinositol (DCI) in the treatment of insulin resistance states. Both isomers have been shown to exert insulin-mimetic action and to lower postprandial glucose. Further, insulin resistance-related diseases were associated to derangements in inositol metabolism. Thus, the aim of this review is to provide current evidence on the potential benefits of inositol isomers (MYO-INS and DCI) in the treatment of disease associated to insulin resistance such as polycystic ovary syndrome (PCOS), gestational diabetes, and metabolic syndrome. Finally, molecular insights into inositol insulin-sensitizing effects will be covered focusing on the possible role of inositol glycans as insulin second messengers.

Original languageEnglish
Article number3058393
JournalInternational Journal of Endocrinology
Volume2016
DOIs
Publication statusPublished - 2016

Fingerprint

Inositol
Insulin
Insulin Resistance
Therapeutics
Gestational Diabetes
Polycystic Ovary Syndrome
Second Messenger Systems
Glucose
Research

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology
  • Endocrine and Autonomic Systems

Cite this

Inositols in the Treatment of Insulin-Mediated Diseases. / Muscogiuri, Giovanna; Palomba, Stefano; Laganà, Antonio Simone; Orio, Francesco.

In: International Journal of Endocrinology, Vol. 2016, 3058393, 2016.

Research output: Contribution to journalReview article

Muscogiuri, Giovanna ; Palomba, Stefano ; Laganà, Antonio Simone ; Orio, Francesco. / Inositols in the Treatment of Insulin-Mediated Diseases. In: International Journal of Endocrinology. 2016 ; Vol. 2016.
@article{f0f05c5c80964858aeb9e0e4671df4ad,
title = "Inositols in the Treatment of Insulin-Mediated Diseases",
abstract = "A growing body of research is currently focused on the role of inositol isomers and in particular myo-inositol (MYO-INS) and D-chiroinositol (DCI) in the treatment of insulin resistance states. Both isomers have been shown to exert insulin-mimetic action and to lower postprandial glucose. Further, insulin resistance-related diseases were associated to derangements in inositol metabolism. Thus, the aim of this review is to provide current evidence on the potential benefits of inositol isomers (MYO-INS and DCI) in the treatment of disease associated to insulin resistance such as polycystic ovary syndrome (PCOS), gestational diabetes, and metabolic syndrome. Finally, molecular insights into inositol insulin-sensitizing effects will be covered focusing on the possible role of inositol glycans as insulin second messengers.",
author = "Giovanna Muscogiuri and Stefano Palomba and Lagan{\`a}, {Antonio Simone} and Francesco Orio",
year = "2016",
doi = "10.1155/2016/3058393",
language = "English",
volume = "2016",
journal = "International Journal of Endocrinology",
issn = "1687-8337",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Inositols in the Treatment of Insulin-Mediated Diseases

AU - Muscogiuri, Giovanna

AU - Palomba, Stefano

AU - Laganà, Antonio Simone

AU - Orio, Francesco

PY - 2016

Y1 - 2016

N2 - A growing body of research is currently focused on the role of inositol isomers and in particular myo-inositol (MYO-INS) and D-chiroinositol (DCI) in the treatment of insulin resistance states. Both isomers have been shown to exert insulin-mimetic action and to lower postprandial glucose. Further, insulin resistance-related diseases were associated to derangements in inositol metabolism. Thus, the aim of this review is to provide current evidence on the potential benefits of inositol isomers (MYO-INS and DCI) in the treatment of disease associated to insulin resistance such as polycystic ovary syndrome (PCOS), gestational diabetes, and metabolic syndrome. Finally, molecular insights into inositol insulin-sensitizing effects will be covered focusing on the possible role of inositol glycans as insulin second messengers.

AB - A growing body of research is currently focused on the role of inositol isomers and in particular myo-inositol (MYO-INS) and D-chiroinositol (DCI) in the treatment of insulin resistance states. Both isomers have been shown to exert insulin-mimetic action and to lower postprandial glucose. Further, insulin resistance-related diseases were associated to derangements in inositol metabolism. Thus, the aim of this review is to provide current evidence on the potential benefits of inositol isomers (MYO-INS and DCI) in the treatment of disease associated to insulin resistance such as polycystic ovary syndrome (PCOS), gestational diabetes, and metabolic syndrome. Finally, molecular insights into inositol insulin-sensitizing effects will be covered focusing on the possible role of inositol glycans as insulin second messengers.

UR - http://www.scopus.com/inward/record.url?scp=84988944609&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84988944609&partnerID=8YFLogxK

U2 - 10.1155/2016/3058393

DO - 10.1155/2016/3058393

M3 - Review article

AN - SCOPUS:84988944609

VL - 2016

JO - International Journal of Endocrinology

JF - International Journal of Endocrinology

SN - 1687-8337

M1 - 3058393

ER -